Durvalumab for the treatment of non-small cell lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Cancer of the Lung and Bronchus - SEER Stat Fact Sheets [Internet]. [cited 2016 Sep 11]. Available from: http://seer.cancer.gov/statfacts/html/lungb.html
   Google Scholar
• Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors [Internet]. [cited 2018 Feb 28]. Available from: http://www.abstractsonline.com/pp8/#!/4292/presentation/12343
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet . 2016 Apr 9;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X.
   PubMedGoogle Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.
   Google Scholar
• Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015 Mar;16(3):257–265.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255–265.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017 22;376(25):2415–2426.
   PubMed Web of Science ®Google Scholar
• Commissioner O of the. Press Announcements - FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing [Internet]. [cited 2018 Feb 22]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm597217.htm
   Google Scholar
• Research C for DE and. Approved Drugs - Durvalumab (Imfinzi) [Internet]. [cited 2018 Feb 20]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
   Google Scholar
• Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–1062.
   PubMed Web of Science ®Google Scholar
• Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med. 2015;373(16):1490–1492.
   PubMed Web of Science ®Google Scholar
• Vanella V, Festino L, Strudel M, et al. PD-L1 inhibitors in the pipeline: promise and progress. Oncoimmunology. 2017;7(1):e1365209.
   PubMed Web of Science ®Google Scholar
• Ibrahim R, Stewart R, Shalabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol. 2015;42(3):474–483.
   PubMed Web of Science ®Google Scholar
• Baverel PG, Dubois VFS, Jin CY, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103(4):631-642. doi: 10.1002/cpt.982.
   Google Scholar
• Antonia SJ, Brahmer JR, Khleif S, et al. Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC). Ann Oncol [Internet]. 2016 Oct 1;27(suppl_6). [cited 2017 Jul 3]. Available from: https://academic.oup.com/annonc/article/27/suppl_6/1216PD/2800089/Phase-1-2-study-of-the-safety-and-clinical.
   Google Scholar
• Antonia SJ, Kim S-W, Spira AI, et al. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer. J Clin Oncol [Internet]. 2016;34(suppl; abstr 9029). [cited 2016 Sep 11]. Available from: http://meetinglibrary.asco.org/content/163695-176.
   Google Scholar
• Garassino MC, Cho B-C, Kim J-H, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19(4):521–536.
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou V, Redman MW, Borghaei H, et al. 83OA phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): lung-MAP Sub-study SWOG S1400A. Ann Oncol [Internet]. 2017 Apr 1;28(suppl_2). [cited 2017 Jul 3]. Available from: https://academic.oup.com/annonc/article/28/suppl_2/mdx091.003/3799664/83OA-phase-II-study-of-durvalumab-MEDI4736-for.
   PubMedGoogle Scholar
• eric. SAFIR02 Lung IFCT-1301 [Internet]. [cited 2017 May 28]. Available from: https://www.ifct.fr/index.php/en/la-recherche/item/1981-safir02-lung-ifct-1301
   Google Scholar
• Planchard D, Yokoi T, McCleod MJ, et al. A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study. Clin Lung Cancer. 2016;17(3):232–236.e1.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895.
   PubMed Web of Science ®Google Scholar
• Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299–308.
   PubMed Web of Science ®Google Scholar
• Mok T, Schmid P, Arén O, et al. 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(4 Suppl):S140–141.
   Google Scholar
• Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2013;8(6):803–805.
   Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S. et al. pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Juergens R, Hao D, Laurie S, et al. MA09.03 cisplatin/pemetrexed + durvalumab +/- tremelimumab in pts with advanced non-squamous NSCLC: A CCTG phase IB study - IND.226. J Thorac Oncol. 2017;12(1):S392–3.
   Web of Science ®Google Scholar
• Gibbons DL, Chow LQ, Kim D-W, et al. 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(4 Suppl):S79.
   Google Scholar
• Yeh T, Jacobs V, Angell H, et al. 60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016 Apr;11(4 Suppl):S80–81.
   Google Scholar
• Weichselbaum RR, Liang H, Deng L, et al. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–379.
   PubMed Web of Science ®Google Scholar
• Siva S, MacManus MP, Martin RF, et al. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015;356(1):82–90.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Ahn M-J, Yang J, Yu H, et al. 136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(4 Suppl):S115.
   Google Scholar